These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 12879633)

  • 41. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin.
    Mück W; Ritter W; Ochmann K; Unger S; Ahr G; Wingender W; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):255-60. PubMed ID: 9208342
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.
    Shitara Y; Sugiyama Y
    Pharmacol Ther; 2006 Oct; 112(1):71-105. PubMed ID: 16714062
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biopharmaceutical profile of cerivastatin: a novel HMG-CoA reductase inhibitor.
    Mück W; Ochmann K; Mazzu A; Lettieri J
    J Int Med Res; 1999; 27(3):107-14. PubMed ID: 10505300
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).
    Igel M; Sudhop T; von Bergmann K
    Eur J Clin Pharmacol; 2001 Aug; 57(5):357-64. PubMed ID: 11599653
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients.
    Mück W; Mai I; Fritsche L; Ochmann K; Rohde G; Unger S; Johne A; Bauer S; Budde K; Roots I; Neumayer HH; Kuhlmann J
    Clin Pharmacol Ther; 1999 Mar; 65(3):251-61. PubMed ID: 10096257
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Failure to continue lipid-lowering drug use following the withdrawal of cerivastatin.
    Mantel-Teeuwisse AK; Klungel OH; Egberts TC; Verschuren WM; Porsius AJ; de Boer A
    Drug Saf; 2004; 27(1):63-70. PubMed ID: 14720086
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The cerivastatin withdrawal crisis: a "post-mortem" analysis.
    Maggini M; Raschetti R; Traversa G; Bianchi C; Caffari B; Da Cas R; Panei P
    Health Policy; 2004 Aug; 69(2):151-7. PubMed ID: 15212862
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions.
    Huynh T; Cordato D; Yang F; Choy T; Johnstone K; Bagnall F; Hitchens N; Dunn R
    Intern Med J; 2002; 32(9-10):486-90. PubMed ID: 12380704
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lack of drug-drug interaction between cerivastatin and nifedipine.
    Sachse R; Brendel E; Mück W; Rohde G; Ochmann K; Horstmann R; Kuhlmann J
    Int J Clin Pharmacol Ther; 1998 Aug; 36(8):409-13. PubMed ID: 9726692
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
    McAdams M; Staffa J; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):229-39. PubMed ID: 18175291
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cerivastatin, genetic variants, and the risk of rhabdomyolysis.
    Marciante KD; Durda JP; Heckbert SR; Lumley T; Rice K; McKnight B; Totah RA; Tamraz B; Kroetz DL; Fukushima H; Kaspera R; Bis JC; Glazer NL; Li G; Austin TR; Taylor KD; Rotter JI; Jaquish CE; Kwok PY; Tracy RP; Psaty BM
    Pharmacogenet Genomics; 2011 May; 21(5):280-8. PubMed ID: 21386754
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of itraconazole on cerivastatin pharmacokinetics.
    Kantola T; Kivistö KT; Neuvonen PJ
    Eur J Clin Pharmacol; 1999 Jan; 54(11):851-5. PubMed ID: 10027660
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risperidone and severe cerivastatin-induced rhabdomyolysis.
    Giner V; Muñoz R; Redón J
    J Intern Med; 2002 Feb; 251(2):177-8. PubMed ID: 11905593
    [No Abstract]   [Full Text] [Related]  

  • 54. Cerivastatin-induced rhabdomyolysis.
    Rodríguez ML; Mora C; Navarro JF
    Ann Intern Med; 2000 Apr; 132(7):598. PubMed ID: 10744612
    [No Abstract]   [Full Text] [Related]  

  • 55. Cerivastatin withdrawn from market.
    Thompson CA
    Am J Health Syst Pharm; 2001 Sep; 58(18):1685. PubMed ID: 11571807
    [No Abstract]   [Full Text] [Related]  

  • 56. [Rhabdomyolysis associated with combined treatment of cerivastatin and gemfibrozil].
    Bosch Rovira T; Llompart Pou JA; Forteza-Rey J
    Rev Clin Esp; 2001 Dec; 201(12):731-2. PubMed ID: 11835892
    [No Abstract]   [Full Text] [Related]  

  • 57. Cerivastatin-induced rhabdomyolysis in a renal transplant on cyclosporin.
    Mora C; Rodríguez ML; Navarro JF
    Transplantation; 2001 Aug; 72(3):551. PubMed ID: 11502997
    [No Abstract]   [Full Text] [Related]  

  • 58. Influence of age on the safety, tolerability, and pharmacokinetics of the novel HMG-CoA reductase inhibitor cerivastatin in healthy male volunteers.
    Mazzu A; Lettieri J; Kaiser L; Mullican W; Heller AH
    J Clin Pharmacol; 1998 Aug; 38(8):715-9. PubMed ID: 9725547
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy.
    Pogson GW; Kindred LH; Carper BG
    Am J Cardiol; 1999 Apr; 83(7):1146. PubMed ID: 10190540
    [No Abstract]   [Full Text] [Related]  

  • 60. Dual hepatic metabolism of cerivastatin--clarifications.
    Guyton JR; Dujovne CA; Illingworth DR
    Am J Cardiol; 1999 Aug; 84(4):497. PubMed ID: 10468102
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.